New ICER and PHIL data show drug launch prices soaring while patients, especially on Medicare, struggle to access needed care ...
Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody candidate toward ...
Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results